The FDA grants priority review to BeiGene's (BGNE) NDA seeking approval for zanubrutinib as a treatment for mantle cell lymphoma.
source https://finance.yahoo.com/news/beigenes-nda-zanubrutinib-gets-priority-150803365.html?.tsrc=rss
The FDA grants priority review to BeiGene's (BGNE) NDA seeking approval for zanubrutinib as a treatment for mantle cell lymphoma.
source https://finance.yahoo.com/news/beigenes-nda-zanubrutinib-gets-priority-150803365.html?.tsrc=rss
blaineonline.finance.blog 